Log in

LON:AVCTAvacta Group Share Price, Forecast & News

GBX 139
+8.00 (+6.11 %)
(As of 07/7/2020 08:51 AM ET)
Today's Range
Now: GBX 139
50-Day Range
MA: GBX 146.58
52-Week Range
Now: GBX 139
Volume2.12 million shs
Average Volume19,964 shs
Market Capitalization£345.83 million
P/E RatioN/A
Dividend YieldN/A
Avacta Group Plc offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom. It operates through two segments, Life Sciences and Animal Health. The company's custom Affimer products are also used in drugs and biomarkers discovery in biotech research and development. In addition, it provides tools and contract services to assist the diagnosis of conditions in animals to enable treatment for veterinarians. The company has a collaboration, licensing, and option agreement with Moderna Therapeutics; research collaboration with OncoSec Medical Incorporated for gene delivery of therapeutic Affimers; and a co-development partnership agreement with Bach Biosciences LLP to develop Affimer drug conjugate therapies. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.
Read More
Avacta Group logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.63 out of 5 stars

Industry, Sector and Symbol

Industry Medical Devices



Sales & Book Value

Annual Sales£3.89 million
Cash FlowGBX 4.63 per share
Book ValueGBX 14.90 per share



Market Cap£345.83 million
Next Earnings DateN/A
OptionableNot Optionable

Receive AVCT News and Ratings via Email

Sign-up to receive the latest news and ratings for AVCT and its competitors with MarketBeat's FREE daily newsletter.

Avacta Group (LON:AVCT) Frequently Asked Questions

How has Avacta Group's stock been impacted by COVID-19 (Coronavirus)?

Avacta Group's stock was trading at GBX 22.75 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AVCT shares have increased by 511.0% and is now trading at GBX 139. View which stocks have been most impacted by Coronavirus.

How were Avacta Group's earnings last quarter?

Avacta Group Plc (LON:AVCT) released its quarterly earnings results on Tuesday, April, 9th. The biotechnology company reported ($4.80) earnings per share (EPS) for the quarter. View Avacta Group's earnings history.

Has Avacta Group been receiving favorable news coverage?

Media headlines about AVCT stock have been trending negative recently, InfoTrie Sentiment reports. The research firm identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Avacta Group earned a coverage optimism score of -2.1 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about Avacta Group.

Who are some of Avacta Group's key competitors?

What other stocks do shareholders of Avacta Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avacta Group investors own include Legal & General Group (LGEN), Skinbiotherapeutics (SBTX), Augean (AUG), Bunzl (BNZL), 7Digital Group (7DIG), Conviviality (CVR), ReNeuron Group (RENE), Bahamas Petroleum (BPC), Best of the Best (BOTB) and Blur Group (BLUR).

Who are Avacta Group's key executives?

Avacta Group's management team includes the following people:
  • Prof. Alastair Smith, CEO & Exec. Director
  • Mr. Tony Gardiner, CFO, Company Sec. & Exec. Director (Age 48)
  • Dr. Michael Albin, Adviser
  • Dr. Matt Johnson, Chief Technology Officer
  • Dr. Amrik Basran Ph.D., Chief Scientific Officer

What is Avacta Group's stock symbol?

Avacta Group trades on the London Stock Exchange (LON) under the ticker symbol "AVCT."

How do I buy shares of Avacta Group?

Shares of AVCT and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Avacta Group's stock price today?

One share of AVCT stock can currently be purchased for approximately GBX 139.

How big of a company is Avacta Group?

Avacta Group has a market capitalization of £345.83 million and generates £3.89 million in revenue each year. Avacta Group employs 114 workers across the globe.

What is Avacta Group's official website?

The official website for Avacta Group is www.avacta.com.

How can I contact Avacta Group?

Avacta Group's mailing address is Unit 20, Ash Way, WETHERBY, LS23 7FA, United Kingdom. The biotechnology company can be reached via phone at +44-1904-217070.

This page was last updated on 7/7/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.